NSSG Chemotherapy Protocol
Dose adjustment for Haematological Toxicity Indication Counts Modification Chronic phase CML (400mg) ANC < 1.0 x 109/L and/or Plt < 50 x 109/L 1. Stop Imatinib until ANC ≥ 1.5 x 10 9/L and Plt ≥ 75 x 10/L 2. Resume treatment at previous dose 3. Recurrence of ANC < 1.0 x 10 9/L and/or Plt < 50 x 10 /L,
Download NSSG Chemotherapy Protocol
Information
Domain:
Source:
Link to this page:
Documents from same domain
CYCLOPHOSPHAMIDE / BORTEZOMIB/ …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed of MM.11 CyBorDex- Amyloidosis Authorised by …
Cyclophosphamide priming prior to PBSC harvest
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology Oxford BMT Programme B.2.20b Page 1 of 3 May 2017 V.5.4 Cyclo prime for Myeloma PSBC Harvest Authorised by: Dr Karthik Ramasamy
ATTENUATED CYCLOPHOSPHAMIDE, THALIDOMIDE & …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed MM.9 CTD - attenuated Authorised by Myeloma lead Dr. Karthik Ramasamy July 2017
Guidelines for the Management of Hypomagnesaemia …
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology H.95 Page 2 of 5 November 2015 V.1.0. Guidelines for the management of hypomagnesaemia in Adult Clinical Haematology
Oxford Myeloma Group
nssg.oxford-haematology.org.ukMM.50 VTDPACE/DTPACE Authorised by Myeloma lead Dr. Karthik Ramasamy June 2022 V. 2.0 of 10 Days Drug Dose Route Comments 1 to 4 Dexamethasone 40 mg daily Oral Continuous daily/ If PBSC harvest planned only for days 1 to 4 Thalidomide (See note below) Start 50 mg and increase up to 100 mg as tolerated Oral Nocte 1 to 4
MATRix (High dose METHOTREXATE, high dose CYTARABINE ...
nssg.oxford-haematology.org.uk- Reduce thiotepa dose to 75% - Reduce methotrexate to 2g/m2 Haematological toxicity In case if inadequate bone marrow recovery (i.e. neutrophils < 1.5x109/L and platelets < 90x109/L on the intended day of re-treatment, delay cycle until counts satisfactory. Doses of the chemotherapy
ISATUXIMAB WITH POMALIDOMIDE AND …
nssg.oxford-haematology.org.ukvolume Initial rate Absence of infusion reaction Rate increment Maximum rate First infusion 250 mL 25 mL/ hour For 60 minutes 25 mL/hour every 30 minutes 150 mL/ hour Second infusion 250 mL 50 mL/ hour For 30 minutes 50 mL/ hour for 30 minutes then increase by 100 mL/ hr every 30 minutes 200 mL/ hour Subsequent infusions
ATRA + ARSENIC TRIOXIDE
nssg.oxford-haematology.org.ukArsenic Trioxide infusion duration may be extended up to 4 hours if vasomotor reactions, e.g. flushing, tachycardia and dizziness, are observed. If patients suffer severe symptoms or hypotension then the infusion should be stopped until recovery and then recommenced at a
High dose METHOTREXATE (high grade NHL CNS …
nssg.oxford-haematology.org.ukadults receiving high-dose methotrexate chemotherapy (doses >1g/m2) - Who develop significant deterioration in renal function (>1.5x ULN and rising, or the presence of oliguria) OR - Have toxic plasma methotrexate level AND - Have been treated with all standard rescue and supportive measures AND
ESHAP and R-ESHAP
nssg.oxford-haematology.org.uk2. Record stage of disease - contrast enhanced CT scan (neck, chest, abdomen and pelvis), ... In order to eliminate the risk of transmitting infective ... After 1-2 cycles with CT or PET-CT. Lymphoma group This is a controlled document and therefore must …
Related documents
People with Learning Disabilities in Scotland: 2017 Health ...
www.healthscotland.scotdemographic profile. The changes include increased longevity and changing patterns of morbidity and mortality. The past decades have seen a similar increase in life expectancy as those found in the general population, except for those with Down syndrome, epilepsy or multiple disabilities (Hosking et al., 2016; Kelly & Kelly, 2012; Coppus, 2013).
NSSG Chemotherapy Protocol
nssg.oxford-haematology.org.ukDose Reduction - Haematological Count Modification Plt < 50 x 109/L or ANC < 0.5 x 109/L or Hb < 80g/L in PV Stop ruxolitinib. Once recovered above these levels, resume ruxolitinib 5mg PO twice a day and gradually increased based on careful monitoring of FBC including white blood cell count differential. Plt < 100 x 109/L or
2019 update of the EULAR recommendations for the ...
ard.bmj.comfor cutaneous, neuropsychiatric, haematological and renal disease. Patients with SLE should be assessed for their antiphospholipid antibody status, infectious and cardiovascular diseases risk profile and preventative strategies be tailored accordingly. The updated recommendations provide physicians and patients with
Test Selection Guide - Dorevitch
www.dorevitch.com.au• Haematological oncology - Fusion probes for common haematological malignancies, e.g. t(9;22) bcr/abl - Multiple myeloma panel - CLL panel • Solid tumour oncology-Paraffin tissue studies - Neu - ALK ROS1 - Oligodendroglioma - Lymphoma Molecular Genetics Inherited Haematological Disorders • Alpha thalassaemia genetic testing
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euAdditive haematological adverse reactions may be expected if cladribine is administered prior to or concomitantly with other substances that affectthe haematological profile(see section4.5). Lymphocyte counts must be determined before initiating MAVENCLAD in year1, before initiating MAVENCLAD in year2,
Lung Ultrasound - European Society of Cardiology
www.escardio.orgHead, Cardiovascular Emergencies and Onco-Haematological Complications Laboratory of Standard and Advanced Echocardiography Federico II University Hospital Vice President, EACVI ... The association of A profile with venous thrombosis (venous scan) favours the diagnosis of pulmonary embolism 81% sensitivity 99% specificity.
NCCP Chemotherapy Regimen Modified FOLFOX-6 Therapy …
www.hse.ieHaematological: Table 2. Dose Modifications for Haematological Toxicity Prior to a Cycles (DAY 1) TOXICITY Dose Level for Subsequent Cycles Grade ANC (x 109/L) Oxaliplatin Fluorouracil If ANC< 1.5 1on Day 1 of cycle, hold treatment, weekly FBC, maximum of 4 weeks ANC ≥ 1.5 within 4 weeks, proceed with treatment at the dose level